We are live on ! Find out more
SCM

Superstring Capital Management Portfolio holdings

AUM $140M
1-Year Est. Return 323.19%
This Fund
S&P 500
This Quarter Est. Return
+58.52%
1 Year Est. Return
+323.19%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$114M
AUM Growth
+$34.9M
Cap. Flow
+$21.4M
Cap. Flow %
18.75%
Top 10 Hldgs %
76.05%
Holding
48
New
9
Increased
7
Reduced
9
Closed
20

Top Buys

Rank Stock Value
1
ORIC icon
Oric Pharmaceuticals
ORIC
+$9.39M
2
GPCR icon
Structure Therapeutics
GPCR
+$8.78M
3
ZLAB icon
Zai Lab
ZLAB
+$7.78M
4
NVCR icon
NovoCure
NVCR
+$5.91M
5
TNGX icon
Tango Therapeutics
TNGX
+$4.61M

Top Sells

Rank Stock Value
1
LEGN icon
Legend Biotech
LEGN
+$5.02M
2
KROS icon
Keros Therapeutics
KROS
+$3.39M
3
ACLX
Arcellx
ACLX
+$3.26M
4
ARWR icon
Arrowhead Research
ARWR
+$2.89M
5
ONC
BeOne Medicines Ltd
ONC
+$1.78M

Sector Composition

Rank Sector Weight
1 Healthcare 97.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZLAB icon
1
Zai Lab
ZLAB
$2.28B
$15.1M 13.25%
626,932
+411,754
+191% +$7.78M
CYTK icon
2
Cytokinetics
CYTK
$10.9B
$11.4M 9.97%
215,798
+28,165
+15% +$1.57M
TERN
3
DELISTED
Terns Pharmaceuticals
TERN
$11.2M 9.84%
1,348,546
+392,004
+41% +$3.23M
GPCR icon
4
Structure Therapeutics
GPCR
$3.45B
$9.97M 8.72%
+227,047
New +$8.78M
ORIC icon
5
Oric Pharmaceuticals
ORIC
$1.11B
$9.73M 8.52%
+949,522
New +$9.39M
TIL icon
6
Instil Bio
TIL
$50.3M
$7.24M 6.34%
+107,545
New +$2.53M
NVCR icon
7
NovoCure
NVCR
$1.84B
$6.14M 5.37%
392,711
+325,819
+487% +$5.91M
BBIO icon
8
BridgeBio Pharma
BBIO
$15.9B
$5.77M 5.05%
226,684
+6,847
+3% +$180K
FATE icon
9
Fate Therapeutics
FATE
$324M
$5.13M 4.49%
1,466,934
+969,574
+195% +$3.77M
CAPR icon
10
Capricor Therapeutics
CAPR
$1.13B
$5.13M 4.49%
+337,347
New +$1.67M
TNGX icon
11
Tango Therapeutics
TNGX
$4.65B
$4.61M 4.04%
599,048
+483,477
+418% +$4.61M
ETNB
12
DELISTED
89bio
ETNB
$4.4M 3.86%
595,203
-85,200
-13% -$716K
NKTX icon
13
Nkarta
NKTX
$186M
$3.35M 2.93%
740,294
-135,705
-15% -$771K
LEGN icon
14
Legend Biotech
LEGN
$4.31B
$2.95M 2.58%
60,515
-94,150
-61% -$5.02M
ZLAB icon
15
CALL
Zai Lab
ZLAB
$2.28B
$2.41M 2.11%
+100,000
New +$1.89M
ZBIO
16
Zenas BioPharma
ZBIO
$1.86B
$1.89M 1.65%
+111,605
New +$2.01M
ALLO icon
17
Allogene Therapeutics
ALLO
$618M
$1.34M 1.17%
478,115
-211,797
-31% -$565K
SYRE icon
18
Spyre Therapeutics
SYRE
$8.7B
$1.1M 0.96%
37,287
-8,284
-18% -$231K
SVRA icon
19
Savara
SVRA
$1.13B
$848K 0.74%
200,000
– –
BMEA icon
20
Biomea Fusion
BMEA
$92.5M
$844K 0.74%
83,554
-83,556
-50% -$543K
TRML
21
DELISTED
Tourmaline Bio
TRML
$748K 0.65%
29,104
-66,125
-69% -$1.1M
ZURA icon
22
Zura Bio
ZURA
$518M
$636K 0.56%
156,626
– –
CABA icon
23
Cabaletta Bio
CABA
$461M
$622K 0.54%
131,795
-8,100
-6% -$46.9K
CRBP icon
24
Corbus Pharmaceuticals
CRBP
$167M
$524K 0.46%
25,401
-31,067
-55% -$1.59M
IMVT icon
25
Immunovant
IMVT
$8.27B
$355K 0.31%
+12,447
New +$367K
1
2

Similar funds

GIM
Guild Investment Management Los Angeles, California $140M AUM 28.67% 1-Year Est. Return
SLWM
Stone Loft Wealth Management West Chester, Pennsylvania $140M AUM
NWA
Northwest Wealth Advisors Bellingham, Washington $140M AUM
WCM
WealthTrak Capital Management Virginia Beach, Virginia $140M AUM 17% 1-Year Est. Return
JD6
J Digital 6 Chicago, Illinois $140M AUM
CPC
CFC Planning Company Cicero, Indiana $140M AUM 22.33% 1-Year Est. Return
CFG
Chapman Financial Group Kailua, Hawaii $140M AUM 15.83% 1-Year Est. Return
RC
Rexford Capital Bellaire, Texas $140M AUM 28.19% 1-Year Est. Return

Superstring Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, Superstring Capital Management held 48 positions worth $114M, up 44% from $79.3M the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Superstring Capital Management deployed $21.4M of net new capital in Q3 2024, opening 9 new positions and adding to 7 existing holdings. Its largest new stake was Oric Pharmaceuticals: 949,522 shares worth $9.73M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was Legend Biotech, an estimated $5.02M trimmed.

  • Superstring Capital Management's largest Q3 2024 buy was Oric Pharmaceuticals: 949,522 shares worth $9.73M.
  • Superstring Capital Management added most to Zai Lab in Q3 2024, an estimated $7.78M increase.
  • Superstring Capital Management's biggest Q3 2024 reduction was Legend Biotech, cutting an estimated $5.02M.
  • Superstring Capital Management fully exited Keros Therapeutics in Q3 2024, selling an estimated $3.39M.
  • Superstring Capital Management's ten largest holdings make up 76% of its $114M portfolio in Q3 2024.
  • Superstring Capital Management opened 9 new positions and closed 20 in Q3 2024.
  • Superstring Capital Management's portfolio value rose 44% quarter-over-quarter to $114M.

Based on Superstring Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.